Literature DB >> 21730120

Pharmacokinetics and ex vivo antimalarial activity of artesunate-azithromycin in healthy volunteers.

Nguyen Trong Chinh1, Nguyen Ngoc Quang, Chu Xuan Anh, Nguyen Xuan Thanh, Bui Dai, Geoffrey W Birrell, Marina Chavchich, Michael D Edstein.   

Abstract

In 18 male healthy subjects, artesunate (200 mg)-azithromycin (1,500 mg) daily for 3 days was found to be well tolerated, with only mild gastrointestinal disturbances reported. The pharmacokinetic properties of artesunate-azithromycin given in combination are comparable to those of the drugs given alone. Artesunate and its major active metabolite, dihydroartemisinin, are responsible for most of the ex vivo antimalarial activity, with a delayed contribution by azithromycin.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21730120      PMCID： PMC3165334          DOI： 10.1128/AAC.00365-11

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  25 in total

1.  In vitro efficacy, resistance selection, and structural modeling studies implicate the malarial parasite apicoplast as the target of azithromycin.

Authors:  Amar Bir Singh Sidhu; Qingan Sun; Louis J Nkrumah; Michael W Dunne; James C Sacchettini; David A Fidock
Journal:  J Biol Chem       Date:  2006-11-15       Impact factor: 5.157

2.  In vitro antimalarial activity of azithromycin, artesunate, and quinine in combination and correlation with clinical outcome.

Authors:  Harald Noedl; Srivicha Krudsood; Wattana Leowattana; Noppadon Tangpukdee; Wipa Thanachartwet; Sornchai Looareesuwan; Robert Scott Miller; Mark Fukuda; Krisada Jongsakul; Kritsanai Yingyuen; Sabaithip Sriwichai; Colin Ohrt; Charles Knirsch
Journal:  Antimicrob Agents Chemother       Date:  2006-11-20       Impact factor: 5.191

Review 3.  Azithromycin: indications for the future?

Authors:  J M Duran; G W Amsden
Journal:  Expert Opin Pharmacother       Date:  2000-03       Impact factor: 3.889

4.  Increased antimalarial activity of azithromycin during prolonged exposure of Plasmodium falciparum in vitro.

Authors:  A E Yeo; K H Rieckmann
Journal:  Int J Parasitol       Date:  1995-04       Impact factor: 3.981

5.  Comparative pharmacokinetics and effect kinetics of orally administered artesunate in healthy volunteers and patients with uncomplicated falciparum malaria.

Authors:  P Teja-Isavadharm; G Watt; C Eamsila; K Jongsakul; Q Li; G Keeratithakul; N Sirisopana; L Luesutthiviboon; T G Brewer; D E Kyle
Journal:  Am J Trop Med Hyg       Date:  2001-12       Impact factor: 2.345

6.  Azithromycin combination therapy for the treatment of uncomplicated falciparum malaria in Bangladesh: an open-label randomized, controlled clinical trial.

Authors:  Kamala Thriemer; Peter Starzengruber; Wasif Ali Khan; Rashidul Haque; Aung Swe Prue Marma; Benedikt Ley; Matthias G Vossen; Paul Swoboda; Jasmin Akter; Harald Noedl
Journal:  J Infect Dis       Date:  2010-08-15       Impact factor: 5.226

Review 7.  Artemisinin drugs: novel antimalarial agents.

Authors:  R N Price
Journal:  Expert Opin Investig Drugs       Date:  2000-08       Impact factor: 6.206

Review 8.  Clinical pharmacology and therapeutic potential of artemisinin and its derivatives in the treatment of malaria.

Authors:  P J de Vries; T K Dien
Journal:  Drugs       Date:  1996-12       Impact factor: 9.546

9.  A randomized controlled pilot trial of azithromycin or artesunate added to sulfadoxine-pyrimethamine as treatment for malaria in pregnant women.

Authors:  Linda Kalilani; Innocent Mofolo; Marjorie Chaponda; Stephen J Rogerson; Alisa P Alker; Jesse J Kwiek; Steven R Meshnick
Journal:  PLoS One       Date:  2007-11-14       Impact factor: 3.240

10.  A multi-center randomised controlled trial of gatifloxacin versus azithromycin for the treatment of uncomplicated typhoid fever in children and adults in Vietnam.

Authors:  Christiane Dolecek; Thi Phi La Tran; Ngoc Rang Nguyen; Thi Phuong Le; Vinh Ha; Quoc Tuan Phung; Cong Du Doan; Thi Be Bay Nguyen; Thanh Long Duong; Bich Ha Luong; Trung Binh Nguyen; Thi Anh Hong Nguyen; Ngoc Dung Pham; Ngoc Lanh Mai; Van Be Bay Phan; Anh Ho Vo; Van Minh Hoang Nguyen; Thu Thi Nga Tran; Thuy Chau Tran; Constance Schultsz; Sarah J Dunstan; Kasia Stepniewska; James Ian Campbell; Song Diep To; Buddha Basnyat; Van Vinh Chau Nguyen; Van Sach Nguyen; Tran Chinh Nguyen; Tinh Hien Tran; Jeremy Farrar
Journal:  PLoS One       Date:  2008-05-21       Impact factor: 3.240
View more
  4 in total

1.  Pharmacokinetics and Ex Vivo Antimalarial Activity of Artesunate-Amodiaquine plus Methylene Blue in Healthy Volunteers.

Authors:  Chu Xuan Anh; Marina Chavchich; Geoffrey W Birrell; Karin Van Breda; Thomas Travers; Kerryn Rowcliffe; Anton R Lord; G Dennis Shanks; Michael D Edstein
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

2.  In Vivo Efficacy and Tolerability of Artesunate-Azithromycin for the Treatment of Falciparum Malaria in Vietnam.

Authors:  Nguyen Chinh Phong; Huynh Hong Quang; Nguyen Xuan Thanh; Trieu Nguyen Trung; Bui Dai; G Dennis Shanks; Marina Chavchich; Michael D Edstein
Journal:  Am J Trop Med Hyg       Date:  2016-05-23       Impact factor: 2.345

3.  Comparison of the Pharmacokinetics and Ex Vivo Antimalarial Activities of Artesunate-Amodiaquine and Artemisinin-Piperaquine in Healthy Volunteers for Preselection Malaria Therapy.

Authors:  Nguyen Ngoc Quang; Marina Chavchich; Chu Xuan Anh; Geoffrey W Birrell; Karin van Breda; Thomas Travers; Kerryn Rowcliffe; Michael D Edstein
Journal:  Am J Trop Med Hyg       Date:  2018-05-03       Impact factor: 2.345

4.  Pyronaridine-Artesunate (Pyramax) for Treatment of Artemisinin- and Piperaquine-Resistant Plasmodium falciparum in the Central Highlands of Vietnam.

Authors:  Nguyen Duc Manh; Nguyen Van Thanh; Huynh Hong Quang; Nguyen Thi Thanh Van; Nguyen Ngoc San; Nguyen Chinh Phong; Geoffrey W Birrell; Michael D Edstein; Kimberly A Edgel; Nicholas J Martin; Marina Chavchich
Journal:  Antimicrob Agents Chemother       Date:  2021-09-27       Impact factor: 5.191
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.